Chimagen Biosciences
PrivateLast Round
M&A
Oct 29, 2024
Company Overview
Chimagen Biosciences operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in October 2024.
Chimagen Biosciences is a clinical-stage biotechnology company that discovers and develops multi-specific T cell-engagers and NK cell-engagers for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chimagen Biosciences Comparables
Compare Chimagen Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innovent Biologics | 82% | |
| Harbour BioMed | 79% | |
| AstraZeneca | 78% |
For institutional investors. Book with your work email.
Chimagen Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Oct 29, 2024 | ||||
| Series B | Oct 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Chimagen Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foresite Capital | Series B |
| Lilly Asia Ventures | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 29, 2024
$300M round led by GSK plc.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- licenses_technologySep 18, 2026
Chimagen licenses a trispecific T-cell engager for multiple myeloma to GlaxoSmithKline plc for up to $750 million; the three targets remain undisclosed, and the program is expected to enter clinical testing in 2027.
For institutional investors. Book with your work email.
Chimagen Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Chimagen Biosciences's valuation, stock price, and market status.
Is Chimagen Biosciences a public or private company?
Chimagen Biosciences is a private company.
What is the current stock price of Chimagen Biosciences?
Chimagen Biosciences is a private company, so its shares have no public market price. Caplight tracks Chimagen Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Chimagen Biosciences worth (valuation)?
Valuation information for Chimagen Biosciences is not publicly available.
Can I buy Chimagen Biosciences stock?
Chimagen Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Chimagen Biosciences's last funding round?
Chimagen Biosciences's most recent funding round was M&A on October 29, 2024.
Who are the main investors in Chimagen Biosciences?
Key investors in Chimagen Biosciences include Foresite Capital, Lilly Asia Ventures.
Will Chimagen Biosciences IPO soon?
No public IPO plans have been announced for Chimagen Biosciences.
How can I track Chimagen Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Chimagen Biosciences's shares on secondary markets.